Journals / Ege Tıp Dergisi / 2015 / Cilt: 54 - Sayı: 3

A case report of neutropenia caused by piperacillin/tazobactam

Piperasilin/tazobaktama bağlı nötropeni gelişen bir olgu sunumu

Pages
148–150
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article, a case with fever, deep thrombocytopenia and neutropenia thought to be due to bone-marrow suppression on the sixteenth day of therapy with PT for the diagnose of soft tissue infection is presented by looking over the similar cases reported from our country.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Piperacillin/tazobactam (PT) is a beta lactam antibiotic which may rarely cause bone-marrow supprresion.
📊
Key Findings & Data:Piperacillin/tazobactam (PT) is a beta lactam antibiotic which may rarely cause bone-marrow supprresion.
💡
Conclusion & Impact:In this article, a case with fever, deep thrombocytopenia and neutropenia thought to be due to bone-marrow suppression on the sixteenth day of therapy with PT for the diagnose of soft tissue infection is presented by looking over the similar cases reported from our country.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Piperacillin/tazobactam (PT) is a beta lactam antibiotic which may rarely cause bone-marrow supprresion. In this article, a case with fever, deep thrombocytopenia and neutropenia thought to be due to bone-marrow suppression on the sixteenth day of therapy with PT for the diagnose of soft tissue infection is presented by looking over the similar cases reported from our country.

Özet

Piperasilin/tazobaktam (PT), nadiren kemik iliği baskılanmasına neden olabilecek beta laktam grubu bir antibiyotiktir. Bu olgu sunumunda yumuşak doku enfeksiyonu tanısı ile PT almakta iken tedavinin on altıncı gününde ateş, kemik iliği baskılanmasına bağlı olduğu düşünülen derin trombositopeni ve nötropeni gelişen bir olgu, ülkemizden bildirilen benzer olgular gözden geçirilerek sunulmuştur.

🔖

Cite This Article

MUTAY, B. S., KUŞCU, F., KAYA, H., DALKIRAN, P. A. (2015). A case report of neutropenia caused by piperacillin/tazobactam. Ege Tıp Dergisi, Cilt: 54 - Sayı: 3, 148–150. https://ajindex.com/articles/204741

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Perry CM, Markham A. Piperacillin/tazobactam: An updated review of its use in the treatment of bacterial infections. Drugs 1999;57(5):805-43
  2. Ruiz-Irastorza G, Barreiro G, Aguirre C. Reversible bone marrow depression by high-dose piperacillin/tazobactam. Br J Haematol 1996;95(4):611-2
  3. Peralta FG, Sánchez MB, Roíz MP, Pena MA, Tejero MA, Arjona R. Incidence of neutropenia during treatment of bone-related infections with piperacillin-tazobactam. Clin Infect Dis 2003;37(11):1568-72
  4. Scheetz MH, McKoy JM, Parada JP, et al. Systematic review of piperacillin-induced neutropenia. Drug Saf 2007;30(4):295-306
  5. Reichardt P, Handrick W, Linke A, Schille R, Kiess W. Leukocytopenia, thrombocytopenia and fever related to piperacillin/tazobactam treatment--a retrospective analysis in 38 children with cystic fibrosis. Infection 1999;27(6):355-6
  6. Lee KW, Chow KM, Chan NP, Lo AO, Szeto CC. Piperacillin/tazobactam induced myelosuppression J Clin Med Res 2009;1(1): 53-5
  7. Özgüler M, Akbulut A. Uzun süreli piperasilin tazobaktam tedavisiyle görülen nötropeni: İki olgu sunumu. Ankem Dergisi 2014;28(1):37-40
  8. Demiraslan H, Gürbüz S, Tomul Z, Çelik İ. Piperasilin/tazobaktam tarafından uyarılmış nötropeni: Bir olgu sunumu. Mediterr J Infect Microb Antimicrob 2012;1(1):2
  9. Uzun G, Onem Y, Hatipoglu M, Turhan V, Mutluoglu M, Ay H. Piperacillin/tazobactam-induced neutropenia, thrombocytopenia, and fever during treatment of a diabetic foot infection. Scan J Infec Dis 2013;45(1):73-6
  10. Ekmekçi A, Yakar F, Tufan F, Demirtürk M, Çağatay A. Piperasilin/tazobaktama bağlı kemik iliği baskılanması ile seyreden bir olgu sunumu. Nobel Medicus 2007; 4(1):28-30.